Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Grapefruit Benefits

CytoDyn Completes Safety Testing Of Cytolin(R): Benchmark For Improved Treatment Of HIV/AIDS
CytoDyn, Inc. (Pink Sheets:CYDY) has completed safety testing of its current inventory of Cytolin®, the Company"s immune-system modulator for managing HIV disease and the public health crisis afflicting communities where the infection is spreading due to unprotected sex and the other risk factors for AIDS. Tests for specific adventitious agents and other quality parameters following purification were performed by the manufacturing facility, Vista Biologicals Corporation of Carlsbad, California. The other safety tests, including in vivo general safety using two animal species, were performed by WuXi AppTec, a fully integrated pharmaceutical, biotechnology and medical-device company with facilities in St. Paul, Minnesota. WuXi AppTec provides R&D services to the biotechnology industry. Since the product is intended for use in a clinical trial, the tests conducted were those required for each new batch of a biologic agent manufactured for use in human research. The Company believes that the test results satisfy the current safety standards for the manufacturing of drugs belonging to the class of biologics. The results are summarized in the table below.
generic viagra online
Sinovac Provides Update On Clinical Trial For H1N1 Vaccine Trials
Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers have received their first shot of the vaccine and, during the three-day observation of safety, the preliminary tests on the A/H1N1 influenza vaccine have indicated that the vaccine is safe and reliable in humans.
News of the day
Shire Selects SAS(R) Drug Development To Handle Clinical Trials Data
SAS, the leader in business analytics, announced that Shire, the global specialty biopharmaceutical company, has selected SAS® Drug Development as the platform for its clinical trials data.
Endocrinology

Support Grows For New Home Based Service For Challenging Mental Patients

A new national service which will provide comprehensive care and support for challenging mental health patients in their own homes following discharge from hospital is being welcomed by lead clinicians and patient advocates. Vicky Wadsworth, head of the mental health department at Roebucks solicitors in Blackburn, which acts on behalf of hundreds of patients, said: "There is a huge gap in care provision that this service can help fill. Health service outreach teams are desperately overstretched and cannot provide the sustained intensive treatment and rehabilitation support that many patients require. In some cases, this means that patients can"t be moved on into the community and so remain confined in secure facilities unnecessarily." Dr Christopher Findlay, a leading community psychiatrist working in Runcorn, said: "There are limits to what Community Mental Health Teams can provide. There are also limited in-patient beds. Any service that offers to work alongside established NHS services to provide intensive safe alternatives to in-patient care is to be welcomed, particularly those that are individually tailored and committed to improved outcomes and the safe social inclusion of patients with mental health difficulties. Working alongside and not replacing existing services is an advantage for responsible clinicians who hope to establish a long term relationship through the journey towards recovery." The service from Gray Healthcare provides sustained support for people who may or may not have been sectioned under the Mental Health Act but who typically have a history of admission, medication and treatment, discharge and re-admission. The service is designed to build self esteem and independence. Patients will be helped to obtain their own tenancy and will then benefit from appropriate support provided by a multidisciplinary team including psychiatric nursing, occupational therapy and psychological services. The majority of patients being referred to the new service are those being considered for discharge from hospital by their responsible clinician under a Community Treatment Order (CTO). This means that the Gray Healthcare clinical team will work closely with NHS staff to create a bespoke care, support and treatment package, tailored to meet the needs and safety of the individual. Jonathan Gray, Chief Executive of Gray Healthcare says: "The Mental Health Act requires us to care for people in the least restrictive environment that is possible and our aim is to help those who have suffered mental illness move from a secure hospital/rehabilitation setting into their own homes with the full range of support necessary to do this safely and successfully. Our goal is a safe and sustainable return to living in the community." Gray Healthcare


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009